- Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) has announced topline results from the Phase 1 trial of its lead product candidate, trans sodium crocetinate (TSC).
- In the trial, transcutaneous oxygen monitoring (TCOM) was used to measure the direct pharmacodynamic effects of TSC on peripheral tissue oxygenation in healthy volunteers.
- Topline results were based upon analyses of primary endpoint data, which indicate, as compared to placebo, a positive dose-response trend in TCOM readings.
- Due to the small number of subjects in each cohort and the inherent variability of tcpO2 measurement, the magnitude of the effect was not statistically significant.
- However, the primary endpoint data trends indicated improved peripheral oxygenation compared to placebo, with no evidence of hyperoxygenation.
- The TCOM Trial was the first of three Oxygenation Trials the Company plans to conduct in 2021, including the Altitude Trial and DLCO trial.
- Diffusion anticipates initiating and completing the DLCO and Altitude Trials in 2H of 2021, with topline results from each study available within two months of their respective completion.
- Diffusion intends to initiate clinical studies in the identified indications during the first half of 2022.
- TSC is under development to enhance oxygen diffusion to tissues with low oxygen levels (hypoxia).
- Price Action: DFFN shares are down 2.57% at $0.74 during the market session on the last check Wednesday.
RBC Capital Maintains Outperform on U.S. Bancorp, Raises Price Target to $66
RBC Capital analyst Gerard Cassidy maintains U.S. Bancorp (NYSE:USB) with a Outperform and raises the price target from $62 to $66.
